Abstract

EVALUATION OF ADVERSE EVENTS FOLLOWING COVID19 IMMUNIZATION AMONG HEALTHCARE WORKERS IN A TERTIARY CARE HOSPITAL

Dr. Virendra Kushwaha, Dr. Pooja Agrawal*, Dr. Rajesh Kumar Verma, Navneet Singh and Dr. Vipul Shukla

ABSTRACT

Two vaccines i) Covishield (a brand of the Oxford–AstraZeneca, manufactured by the Serum Institute of India) and ii) Covaxin (developed by Bharat Biotech) received approval for Covid-19 immunisation in India. So, the objective of our study is to see the adverse events following Covid-19 vaccination in a tertiary care centre. This is a prospective observational study. Data is collected among health care workers at G.S.V.M. Medical College Kanpur, who had received Covid-19 vaccine during phase I. In our study, the most common reported Adverse Events Following Immunization (AEFI) is injection site pain (16.08%) followed by pyrexia (11.89%) and general body pain (9.09%). AEFI is more prevalent in males (62%) than females (38%) and the maximum number of AEFIs are general Disorders and administration site conditions (48.25%), 93.71% of which is Type A (100% of which is nonserious type). From this study, we concluded that most of the AEFIs are Type A and of mild severity (common after any kind of vaccination), none of which is life-threatening. So, in our view, the vaccine is safe and free from major side effects.

Keywords: Covid-19, Vaccine, AEFI, Covishield.